1662-P: Lower Expression of Bile Acid Transporters and Fibroblast Growth Factor 19 in Mucosa Biopsies from the Ileocecal Region in Persons with Type 2 Diabetes Compared with Healthy Controls

Abstract Background The role of serum fibroblast growth factor 19 (FGF19) in arteriosclerosis is not well known. In the present study, we aimed to explore whether serum FGF19 levels were related to arteriosclerosis parameters, including arterial stiffness and atherogenic index of plasma (AIP), in patients with type 2 diabetes (T2D).Methods A total of 200 patients with type 2 diabetes and 50 healthy controls were recruited for this study from Apr 2017 to Oct 2018. Serum FGF19 levels, arterial stiffness assessed by brachial ankle pulse wave velocity (baPWV), and AIP assessed by the triglyceride to high-density lipoprotein cholesterol (TG/HDL-c) ratio were measured in those subjects. In addition, other relevant clinical data were also collected. Results Serum FGF19 levels in T2D patients were significantly lower than those in healthy controls (p < 0.05). The arteriosclerosis parameters, including baPWV and AIP, significantly decreased across ascending tertiles of serum FGF19 levels (all p for trend < 0.001). Moreover, the baPWV and AIP were all inversely correlated with serum FGF19 levels (r = –0.351 and –0.303, respectively, p < 0.001). Furthermore, after adjusting for other clinical covariates by multiple linear regression analyses, the serum FGF19 levels were independently associated with baPWV (β = –0.20, t = –2.23, p = 0.029) and AIP (β = –0.28, t = –2.66, p = 0.010).Conclusions The serum FGF19 levels were independently and inversely associated with baPWV and AIP, which indicate that serum FGF19 may have a protective role in atherosclerosis in patients with T2D.

Download Full-text

Serum Fibroblast Growth Factor 19 and Total Bile Acid Concentrations Are Potential Biomarkers of Hepatocellular Carcinoma in Patients with Type 2 Diabetes Mellitus

BioMed Research International ◽

10.1155/2020/1751989 ◽

2020 ◽

Vol 2020 ◽

pp. 1-9

Author(s):

Yi Sun ◽

Minxia Zhu ◽

Hui Zhao ◽

Xiaoqing Ni ◽

Renan Chang ◽

...

Keyword(s):

Diabetes Mellitus ◽

Hepatocellular Carcinoma ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Bile Acid ◽

Growth Factor ◽

Fibroblast Growth ◽

Newly Diagnosed ◽

Fibroblast Growth Factor 19

Purpose. Type 2 diabetes mellitus (T2DM) carries a high risk of hepatocellular carcinoma (HCC). Both serum fibroblast growth factor 19 (FGF19) and bile acid concentrations are associated with T2DM and HCC. We aimed at evaluating the relationships between FGF19 and bile acid concentrations and HCC in patients with T2DM. Methods. Twenty-seven healthy volunteers (control group), 27 patients with T2DM (T2DM group), 16 patients with newly diagnosed HCC (HCC group), and 10 T2DM patients with newly diagnosed HCC (T2DM-HCC group) were studied at the Affiliated Hospital of Nantong University between June 2016 and June 2017. The serum concentrations of serum FGF19 and total bile acids (TBA) were measured in all the participants. Correlation analysis and multiple stepwise regression analysis of the FGF19 and TBA concentrations were performed in all the participants and in the four groups. Results. The concentrations of FGF19 were 220.5 pg/ml, 185.1 pg/ml, 115.8 pg/ml, and 70.4 pg/ml in the HCC, T2DM-HCC, control, and T2DM groups, respectively (p<0.001), and the TBA concentrations were 21.75 μmol/l, 14.25 μmol/l, 3.6 μmol/l, and 3.1 μmol/l (p<0.001). There were positive correlations between the FGF19 and TBA concentrations across all the participants (r = 0.777; p<0.001), and in the control (r = 0.400; p=0.039), T2DM (r = 0.477; p=0.012), HCC (r = 0.684; p=0.003), and T2DM-HCC (r = 0.673; p=0.033) groups. Conclusions. Simultaneous increase of serum FGF19 and TBA levels may be used as indicators of HCC screening at early stage in patients with T2DM.

Download Full-text

Association of serum fibroblast growth factor 19 levels with arteriosclerosis parameters assessed by arterial stiffness and atherogenic index of plasma in patients with type 2 diabetes

10.21203/rs.2.24087/v2 ◽

2020 ◽

Author(s):

Wangshu Liu ◽

Mengjie Tang ◽

Tianli Xu ◽

Jianbin Su ◽

Xue-Qin Wang ◽

...

Keyword(s):

Type 2 Diabetes ◽

Growth Factor ◽

Arterial Stiffness ◽

Fibroblast Growth Factor ◽

Atherogenic Index ◽

Healthy Controls ◽

Fibroblast Growth ◽

Atherogenic Index Of Plasma ◽

Fibroblast Growth Factor 19

Abstract Background The role of serum fibroblast growth factor 19 (FGF19) in the arteriosclerosis is not well known. In the present study, we aimed to explore whether serum FGF19 levels were related to the arteriosclerosis parameters, including arterial stiffness and atherogenic index of plasma (AIP), in patients with type 2 diabetes (T2D). Methods 200 patients with type 2 diabetes and 50 healthy controls were recruited for this study from Apr 2017 to Oct 2018. Serum FGF19 levels, arterial stiffness assessed by brachial ankle pulse wave velocity (baPWV), and AIP assessed by ratio of triglyceride to high-density lipoprotein cholesterol (TG/HDL-c) were measured in those subjects. In addition, other relevant clinical data were also collected. Results Serum FGF19 levels in T2D patients were significantly lower than that in healthy controls ( p < 0.01). The arteriosclerosis parameters, including baPWV and AIP, significantly decreased across ascending tertiles of serum FGF19 levels (all p for trend < 0.001). Moreover, the baPWV and AIP were all inversely correlated with serum FGF19 levels ( r = –0.351 and –0.303, respectively, p < 0.001). Furthermore, after adjusting for other clinical covariates by multiple linear regression analyses, the serum FGF19 levels were independently associated with baPWV ( β = –0.20, t = –2.23, p = 0.029) and AIP ( β = –0.28, t = –2.66, p = 0.010) in patients with T2D. Conclusions The serum FGF19 levels were independently and inversely associated with baPWV and AIP in patients with T2D, which indicate serum FGF19 may plays a protect role against pathogenesis of the atherosclerosis in those patients.

Download Full-text